Logo

Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

Share this

Sierra Oncology Reports Results of Momelotinib in P-III (MOMENTUM) Study for the Treatment of Myelofibrosis

Shots:

  • The P-III (MOMENTUM) study evaluating momelotinib vs danazol in 195 patients with myelofibrosis who were symptomatic & anemic across 21 countries. The company is expected the NDA submission in Q2’22
  • The trial met all 1EPs & 2EPs i.e., patients achieved  benefit on symptoms, anemia & splenic size, TSS reduction of >50% (25% vs 9%), transfusion independence (31% vs 20%), SRR >35% (23% vs 3%), rate of Grade 3 or worse AEs (54% & 65%), serious TEAEs were 35% & 40%
  • Additionally, mean baseline characteristics for all patients were TSS of 27, Hgb of 8 g/dL & platelet count of 145 x 10 9/L. Momelotinib is a potent, selective & orally bioavailable JAK1/2 & ACVR1/ALK2 inhibitor

Ref: Businesswire | Image: Sierra

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions